The McKinsey Week in Charts

Mining the C-suite for women leaders

Shattering the glass ceiling is a feat for women in many industries, but in mining this effort is particularly challenging. Mining is a “laggard among laggards,” with women representing only 13 percent of C-suite roles, according to results of our global survey.

To read the article, see “Why women are leaving the mining industry and what mining companies can do about it,” September 13, 2021.

To be precise

Smaller US manufacturers have a hard time keeping pace with their bigger brothers. How can they catch up? Our new research suggests that three factors make most of the difference: precision in manufacturing, the ability to handle geometrically complex designs, and throughput speed. Those are the core ingredients of McKinsey’s new Manufacturing Process Innovation Index.

To read the article, see “Manufacturing process innovation for industrials,” September 16, 2021.

The mothers of invention

After World War II, companies came up with dishwashers and clothes dryers to assist working women. After the SARS epidemic, Asian innovators made remote banking and buying easier. After the 2008 financial crisis, companies came up with the sharing economy, to make the most of stranded assets and an unemployed workforce. The lesson? Those who innovate through a crisis come out stronger.

To read the podcast transcript, see “Innovation—the launchpad out of the crisis,” September 15, 2021.

Streamlining submissions for faster drug approvals

The development of vaccines for COVID-19 made clear the value of being first to market. Pharmaceutical companies that optimize their drug-submission process can expedite the approval timeline from an average of about eight months by collaborating with regulators and simplifying strategies.

To read the article, see “Getting strategic about new-product submissions in the pharma industry,” September 16, 2021.

COVID-19: How does it compare with other diseases?

As countries make the transition from viewing COVID-19 as a special threat to managing it as an endemic disease, it may be helpful to compare the progress of the pandemic with other health conditions that countries have grown comfortable in managing. Click through to see data for the United States, United Kingdom, and France.

To read the article, see “COVID-19: A comparison with other public-health burdens,” September 8, 2021

www.mckinsey.com